Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Condition(s):Colorectal Adenocarcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Adenocarcinoma; Gastric Adenocarcinoma; Esophageal AdenocarcinomaLast Updated:April 2, 2018Terminated